Company news

Transgene SA news in 2025

Transgene SA's news releases, calls and decks from 2025, newest first.

View company

Transgene announces the resume of trading of its shares on Euronext Paris as of the opening of the markets

November 26, 2025

Transgene Successfully Completes a Fundraising of c. €105 Million

November 26, 2025

Correction: Transgene Announces the Temporary Suspension of Trading of its Shares on Euronext Paris

November 25, 2025

Transgene Announces the Temporary Suspension of Trading of its Shares on Euronext Paris

November 25, 2025

Correction: Transgene launches a fundraising campaign for approximately 105 million euros

November 25, 2025

Transgene launches a fundraising campaign for approximately 105 million euros

November 25, 2025

Transgene to Showcase Potential of Proprietary VacDesignR® Computational Tool to Optimize Individualized Therapeutic Cancer Vaccines

November 6, 2025

Transgene Provides Business and Financial Update for Q3 2025

November 4, 2025

Transgene to Present New Immunological Data from Phase I Trial of Individualized Therapeutic Cancer Vaccine, TG4050, at SITC 2025

October 3, 2025

Transgene’s Individualized Neoantigen Therapeutic Cancer Vaccine TG4050 Delivers Positive Randomized Phase I Data  Randomization to be Completed in Phase II Part in Q4 2025

September 16, 2025

Societe Generale: shares & voting rights as of 31 August 2025

September 9, 2025

Transgene Appoints Seasoned Industry Executive Emmanuelle Quilès to Board of Directors as Independent Director

July 9, 2025

Balance sheet of the liquidity contract with Natixis Oddo BHF SCA as of June 30, 2025

July 8, 2025

Transgene Completes Initial Patient Screening in Phase II Part of TG4050 Trial in Operable Head and Neck Cancer

June 19, 2025

Transgene to Participate in Upcoming Meetings with Biotech Industry Leaders

June 13, 2025

Transgene to Host Webcast on Positive TG4050 Head and Neck Cancer Data Presented at ASCO 2025

June 3, 2025

Transgene and NEC Present Durable Disease-Free Survival and Sustained T Cell Responses at 24 Months with Individualized Cancer Vaccine TG4050

June 1, 2025

Transgene to Present 24-month Disease-Free Survival Data from All Patients in Phase I Part of Trial of Individualized Cancer Vaccine, TG4050, at ASCO 2025

May 22, 2025

Transgene's Combined General Meeting of May 15, 2025

May 15, 2025

Calls in 2025

Decks in 2025